Profile data is unavailable for this security.
About the company
TFF Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company engaging patented rapid freezing technology to develop and transform medicine into potent dry powder. It is focused on developing and commercializing drug products based on its patented Thin Film Freezing (TFF) technology platform. Its TFF technology platform has an applicability to convert any drug, including vaccines, small and large molecules, and biologics, into a dry powder for inhalation, or for topical delivery to the eyes, nose and the skin. TFF Pharmaceuticals has two lead drug candidates in the clinic: TFF TAC (Tacrolimus Inhalation Powder) and TFF VORI (Voriconazole Inhalation Powder). TFF TAC is an inhaled dry powder formulation of tacrolimus, for the prophylaxis of organ rejection in patients receiving lung transplants, in combination with other immunosuppressants. TFF VORI is an inhaled dry powder formulation of voriconazole, for the treatment and prophylaxis of invasive pulmonary aspergillosis.
- Revenue in USD (TTM)885.71k
- Net income in USD-19.93m
- Incorporated2018
- Employees19.00
- LocationTFF Pharmaceuticals Inc2600 Via Fortuna Ste 360AUSTIN 78746-7983United StatesUSA
- Fax+1 (302) 655-5049
- Websitehttps://tffpharma.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Titan Pharmaceuticals Inc | 87.00k | -4.95m | 5.95m | 4.00 | -- | 0.978 | -- | 68.41 | -6.41 | -6.41 | 0.1119 | 6.66 | 0.0197 | -- | 1.23 | 21,750.00 | -112.41 | -96.80 | -170.59 | -156.65 | -- | -- | -5,694.25 | -406.26 | -- | -415.19 | 0.00 | -- | -66.97 | -51.16 | 45.43 | -- | -65.61 | -- |
| Virios Therapeutics Inc | 0.00 | -5.07m | 5.97m | 4.00 | -- | -- | -- | -- | -0.2673 | -0.2673 | 0.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 56.76 | -- | -- | -- |
| Xenetic Biosciences Inc | 2.44m | -4.47m | 6.01m | 4.00 | -- | 0.6926 | -- | 2.46 | -2.92 | -2.92 | 1.59 | 5.63 | 0.2116 | -- | -- | 611,240.00 | -38.71 | -48.91 | -41.54 | -52.82 | -- | -- | -182.95 | -682.42 | -- | -- | 0.00 | -- | 48.80 | -- | 36.90 | -- | -- | -- |
| Enveric Biosciences Inc | 0.00 | -15.11m | 6.05m | 7.00 | -- | 0.8777 | -- | -- | -6.46 | -6.46 | 0.00 | 0.8887 | 0.00 | -- | -- | 0.00 | -122.02 | -104.94 | -178.49 | -156.88 | -- | -- | -- | -243.54 | -- | -- | 0.00 | -- | -- | -- | 7.14 | -- | -- | -- |
| Applied DNA Sciences Inc | 5.52m | -12.50m | 6.09m | 53.00 | -- | -- | -- | 1.10 | -17.13 | -17.13 | 7.67 | -0.0558 | 0.3893 | 10.38 | 4.64 | 104,110.80 | -87.15 | -88.57 | -111.09 | -121.91 | 33.98 | 44.35 | -223.89 | -113.26 | 1.54 | -- | -- | -- | -26.43 | 27.92 | -18.73 | -- | 33.80 | -- |
| Adial Pharmaceuticals Inc | 0.00 | -11.24m | 6.14m | 4.00 | -- | 0.9605 | -- | -- | -6.01 | -3.75 | 0.00 | 1.51 | 0.00 | -- | -- | 0.00 | -212.33 | -182.35 | -273.26 | -235.45 | -- | -- | -- | -- | -- | -20.20 | 0.00 | -- | -- | -- | 35.14 | -- | -- | -- |
| Cannabis Bioscience Internatnl Hlgs Inc | 56.94m | 6.94m | 6.23m | 389.00 | 0.0011 | 0.0001 | 0.6752 | 0.1094 | 0.5328 | 0.5328 | 4.29 | 4.92 | 0.5917 | 62.81 | 1.45 | 146,384.30 | 7.83 | -- | 11.73 | -- | 31.96 | -- | 13.24 | -- | 0.6856 | 50.75 | 0.0631 | -- | 12.79 | -- | 177.84 | -- | -- | -- |
| Reliv International Inc | 35.13m | -175.48k | 6.35m | 208.00 | -- | 0.9165 | 15.88 | 0.1808 | -0.1005 | -0.1005 | 20.12 | 6.55 | 2.09 | 8.02 | 228.49 | -- | -1.05 | -4.65 | -1.47 | -6.06 | 40.90 | 41.98 | -0.4996 | -2.33 | 1.07 | -- | 0.1064 | -- | -2.94 | -9.37 | 76.65 | -- | -35.85 | -- |
| TFF Pharmaceuticals Inc | 885.71k | -19.93m | 6.38m | 19.00 | -- | 0.9784 | -- | 7.21 | -10.20 | -10.20 | 0.4371 | 2.11 | 0.0647 | -- | 3.72 | 46,616.32 | -145.46 | -79.57 | -181.57 | -83.41 | -- | -- | -2,249.83 | -8,687.66 | -- | -- | 0.00 | -- | 48.01 | -- | 33.13 | -- | -- | -- |
| Genprex Inc | 0.00 | -27.63m | 6.53m | 26.00 | -- | 0.6828 | -- | -- | -19.18 | -19.18 | 0.00 | 4.55 | 0.00 | -- | -- | 0.00 | -153.97 | -92.06 | -202.83 | -98.32 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -29.99 | -- | -7.13 | -- |
| Tenax Therapeutics Inc | 0.00 | -10.10m | 6.78m | 5.00 | -- | 0.5451 | -- | -- | -24.52 | -24.52 | 0.00 | 6.35 | 0.00 | -- | -- | 0.00 | -67.96 | -199.16 | -75.66 | -285.64 | -- | -- | -- | -- | -- | -105.12 | 0.0322 | -- | -- | -- | 30.21 | -- | -- | -- |
| Pulmatrix Inc | 11.68m | -8.85m | 6.83m | 22.00 | -- | 0.3591 | -- | 0.5845 | -2.42 | -2.42 | 3.20 | 5.21 | 0.3517 | -- | 17.84 | 531,090.90 | -26.63 | -46.91 | -30.21 | -58.12 | -- | -- | -75.73 | -238.04 | -- | -- | 0.00 | -- | 20.21 | 116.62 | 25.03 | -- | 104.29 | -- |
| Kazia Therapeutics Ltd (ADR) | 15.01k | -13.61m | 6.85m | 12.00 | -- | 0.7396 | -- | 456.72 | -0.8257 | -0.8257 | 0.0008 | 0.3515 | 0.0007 | -- | 73.97 | -- | -63.98 | -46.35 | -82.39 | -54.75 | -- | -- | -90,714.45 | -497.17 | -- | -- | 0.1297 | -- | 979.43 | -28.31 | 18.19 | -- | -- | -- |
Data as of May 31 2024. Currency figures normalised to TFF Pharmaceuticals Inc's reporting currency: US Dollar USD
14.00%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Carlson Capital LPas of 31 Mar 2024 | 193.96k | 7.70% |
| DRW Securities LLCas of 31 Mar 2024 | 40.00k | 1.59% |
| Westside Investment Management LLCas of 31 Mar 2024 | 39.23k | 1.56% |
| The Vanguard Group, Inc.as of 31 Mar 2024 | 34.37k | 1.36% |
| Geode Capital Management LLCas of 31 Mar 2024 | 17.34k | 0.69% |
| Renaissance Technologies LLCas of 31 Mar 2024 | 13.20k | 0.52% |
| BlackRock Fund Advisorsas of 31 Mar 2024 | 7.80k | 0.31% |
| Allianz Spravcovska Spolocnost ASas of 31 Dec 2022 | 4.66k | 0.19% |
| UBS Financial Services, Inc.as of 31 Mar 2024 | 1.13k | 0.05% |
| University of Texas Investment Management Co.as of 31 Mar 2024 | 882.00 | 0.04% |
More ▼
Data from 30 Jun 2023 - 31 Mar 2024Source: FactSet Research Systems Inc.
